

## NIH AIDS Reagent Program

20301 Century Boulevard Building 6, Suite 200 Germantown, MD 20874 USA

Phone: 240 686 4740 Fax: 301 515 4015 aidsreagent.org

## **DATA SHEET**

Reagent: Anti-HIV-1 gp120 Monoclonal (4G10)

Catalog Number: 2534

Lot Number: 130406

**Release Category:** D

Provided: 1 mL tissue culture supernatant.

Host: Balb/c splenocyte x Ag8658 myeloma.

Special Characteristics: Raised against hybrid HBcAg/HIV-1 gp120 (aa 303-327) particles. Recognizes LAI gp160 and the V3 peptide RIQRGPGRAFVTGK (aa 308-322) in ELISA. Also recognizes gp120 in Western blots and IFA of LAI-infected H9 cells. The antibody inhibits syncytium formation, RT activity, and p24 production in vitro (100% over 20 days).

ARP3012 4G10 Mab Recognizing ARP656 HIV-1 gp160 protein.

Endotoxin: 17.152 EU/mL\*

\*NOTE: Endotoxin has been shown to induce chemokines and other soluble HIV and SIV inhibitory factors in primary cultures of PBMC, monocytes and macrophages (Verani et al., J Exp Med 185:805-816, 1997; J Immunol 168:6388-6396, 2002; Montefiori in preparation). Thus, caution is advised when using this reagent for in vitro studies

involving primary cells.

Recommended Storage:

Keep at 4°C for short term storage and -80°C for long term storage. Avoid freeze-thaw

cycles as reagent degradation may result.

Contributor: Dr. Albrecht von Brunn, Courtesy of the MRC AIDS Directed Programme.

Isotype: IgG<sub>1</sub>.

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.

REV: 12/08/2017 Page 1 of 2 References:

von Brunn A, Brand M, Reichhuber C, Morys-Wortman C, Deinhardt F, Schödel F. Principal neutralizing domain of HIV-1 is highly immunogenic when expressed on the

surface of hepatitis B core particles. Vaccine 11:817-824, 1993.

von Brunn A, Reichhuber C, Brand M, Bechowsky B, Gürtler L, Eberle J, Kleinschmidt A, Erfle V, Schödel F. The principal neutralizing determinant (V3) of HIV-1 induces HIV-1-neutralizing antibodies upon expression on HBcAg particles. In: Vaccines 93,

Cold Spring Harbor Press; Cold Spring Harbor, New York, pp 159-165, 1993.

NOTE:

Acknowledgment for publications should read "The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: Anti-HIV-1  $\,$ gp120 Monoclonal (4G10) from Dr. Albrecht von Brunn, Courtesy of the MRC AIDS Directed Programme." Also include the references cited above in any publications.

**Last Updated** December 08, 2017

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.

REV: 12/08/2017 Page 2 of 2